NO328500B1 - Polymorfer av en epothilon-analog - Google Patents

Polymorfer av en epothilon-analog Download PDF

Info

Publication number
NO328500B1
NO328500B1 NO20030707A NO20030707A NO328500B1 NO 328500 B1 NO328500 B1 NO 328500B1 NO 20030707 A NO20030707 A NO 20030707A NO 20030707 A NO20030707 A NO 20030707A NO 328500 B1 NO328500 B1 NO 328500B1
Authority
NO
Norway
Prior art keywords
approx
solution
hours
formula
mixture
Prior art date
Application number
NO20030707A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030707L (no
NO20030707D0 (no
Inventor
Denis Favreau
Timothy M Malloy
John D Dimarco
Jack Z Gougoutas
Imre M Vitez
Martha Davidovich
Michael Galella
Zhenrong Guo
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22845469&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO328500(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20030707D0 publication Critical patent/NO20030707D0/no
Publication of NO20030707L publication Critical patent/NO20030707L/no
Publication of NO328500B1 publication Critical patent/NO328500B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20030707A 2000-08-16 2003-02-14 Polymorfer av en epothilon-analog NO328500B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22559000P 2000-08-16 2000-08-16
PCT/US2001/024540 WO2002014323A2 (en) 2000-08-16 2001-08-01 Polymorphs of an epothilone analog

Publications (3)

Publication Number Publication Date
NO20030707D0 NO20030707D0 (no) 2003-02-14
NO20030707L NO20030707L (no) 2003-04-15
NO328500B1 true NO328500B1 (no) 2010-03-01

Family

ID=22845469

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030707A NO328500B1 (no) 2000-08-16 2003-02-14 Polymorfer av en epothilon-analog

Country Status (42)

Country Link
US (4) US6689802B2 (sl)
EP (1) EP1309597B1 (sl)
JP (1) JP5046467B2 (sl)
KR (1) KR100810342B1 (sl)
CN (1) CN1269821C (sl)
AR (1) AR034259A1 (sl)
AT (1) ATE366735T1 (sl)
AU (2) AU8108201A (sl)
BG (1) BG66132B1 (sl)
BR (1) BR0113234A (sl)
CA (1) CA2418109C (sl)
CY (1) CY1107758T1 (sl)
CZ (1) CZ305523B6 (sl)
DE (1) DE60129334T2 (sl)
DK (1) DK1309597T3 (sl)
EE (1) EE05273B1 (sl)
ES (1) ES2288518T3 (sl)
GE (1) GEP20053495B (sl)
HK (1) HK1052010A1 (sl)
HR (1) HRP20030190B1 (sl)
HU (1) HU229314B1 (sl)
IL (2) IL153993A0 (sl)
IS (1) IS2845B (sl)
LT (1) LT5138B (sl)
LV (1) LV13032B (sl)
MX (1) MXPA03001431A (sl)
MY (1) MY134129A (sl)
NO (1) NO328500B1 (sl)
NZ (1) NZ523722A (sl)
PE (1) PE20020290A1 (sl)
PL (1) PL205628B1 (sl)
PT (1) PT1309597E (sl)
RO (1) RO123296B1 (sl)
RU (1) RU2272039C2 (sl)
SI (1) SI21100B (sl)
SK (1) SK287876B6 (sl)
TW (1) TWI320040B (sl)
UA (1) UA75365C2 (sl)
UY (1) UY26886A1 (sl)
WO (1) WO2002014323A2 (sl)
YU (1) YU12103A (sl)
ZA (1) ZA200300522B (sl)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
EP1386922B1 (en) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
CA2434526C (en) * 2001-01-25 2011-11-01 Bristol Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
MXPA03006485A (es) * 2001-01-25 2003-09-22 Bristol Myers Squibb Co Formulacion parenteral que contiene analogos de epotilona.
CA2438610A1 (en) 2001-02-20 2002-08-29 Francis Y. F. Lee Treatment of refractory tumors using epothilone derivatives
ATE554756T1 (de) * 2001-03-14 2012-05-15 Bristol Myers Squibb Co Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
IL163774A0 (en) * 2002-03-08 2005-12-18 Univ Newcastle Combinations comprising epothilone derivatives andalkylating agents
SI1767535T1 (sl) * 2002-08-23 2010-03-31 Sloan Kettering Inst Cancer Sinteza epotilonov njihovih intermediatov analogov in uporaba le teh
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
PL1817013T3 (pl) 2004-11-18 2009-01-30 Bristol Myers Squibb Co Dojelitowa powlekana peletka zawierająca Ixabepilone
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
EP2634252B1 (en) 2005-02-11 2018-12-19 University of Southern California Method of expressing proteins with disulfide bridges
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
US7693596B2 (en) 2005-12-14 2010-04-06 Dell Products L.P. System and method for configuring information handling system integrated circuits
US7919108B2 (en) * 2006-03-10 2011-04-05 Cook Incorporated Taxane coatings for implantable medical devices
US20080286325A1 (en) * 2006-01-05 2008-11-20 Med Institute, Inc. Cyclodextrin elution media for medical device coatings comprising a taxane therapeutic agent
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
JP2009532035A (ja) 2006-03-31 2009-09-10 ブリストル−マイヤーズ スクイブ カンパニー 微小管安定化剤に対する感受性を決定するためのバイオマーカーおよび方法
EP2029156A4 (en) * 2006-05-01 2010-07-21 Univ Southern California POLY THERAPY FOR TREATING CANCER
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
KR20090038902A (ko) * 2006-08-16 2009-04-21 노파르티스 아게 에포틸론 b의 결정 형태 및 제약 조성물에서의 용도
US8463852B2 (en) * 2006-10-06 2013-06-11 Oracle International Corporation Groupware portlets for integrating a portal with groupware systems
WO2008103916A2 (en) * 2007-02-23 2008-08-28 The Trustees Of Columbia Univeristy In The City Of New York Compositions and methods for treating cancer or a neurotrophic disorder
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
SG10201501095WA (en) 2010-02-12 2015-04-29 Pharmascience Inc Iap bir domain binding compounds
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
KR20130086534A (ko) * 2010-06-01 2013-08-02 플러스 케미칼스, 에스.에이. 익사베필론의 고체 형태
WO2013092998A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of antibodies
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
EP2916872B1 (en) 2012-11-09 2019-02-27 Innate Pharma Recognition tags for tgase-mediated conjugation
CN103183681B (zh) * 2013-03-06 2016-01-13 浙江海正药业股份有限公司 伊沙匹隆的新晶型及其制备方法
WO2014140300A1 (en) 2013-03-15 2014-09-18 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
EP3010547B1 (en) 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
EP3010548A1 (en) 2013-06-21 2016-04-27 Innate Pharma Enzymatic conjugation of polypeptides
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues
WO2021152107A1 (en) 2020-01-31 2021-08-05 Oncology Venture ApS Methods for predicting ixabepilone responsiveness in cancer patients
CN112409366A (zh) * 2020-11-30 2021-02-26 湖北宏中药业股份有限公司 一种伊沙匹隆二聚体的高收率制备方法
CN112457320A (zh) * 2020-11-30 2021-03-09 湖北宏中药业股份有限公司 一种提高伊沙匹隆合成反应速率的方法
CN112375085A (zh) * 2020-11-30 2021-02-19 湖北宏中药业股份有限公司 一种伊沙匹隆反应液的高收率高纯度处理方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1000809A (en) * 1960-11-02 1965-08-11 James Oakes & Company Riddings Pipe manufacture
DE2308418B2 (de) * 1972-06-21 1976-04-08 Petzetakis, Aristovoulos George, Moschaton, Piräus (Griechenland) Verfahren und vorrichtung zum herstellen eines insbesondere grosskalibrigen rohres aus thermoplastischem kunststoff
JPS5240337B2 (sl) * 1973-01-29 1977-10-12
SE386365B (sv) * 1973-07-25 1976-08-09 L Brendling Behallare av plast, gummi eller annat bojligt material, spec. avsedd for uppsamling av urin och/eller fekalier
JPS6398413A (ja) * 1986-10-15 1988-04-28 Smc Corp 二重管およびその連続製造法
DE3927569A1 (de) * 1989-08-21 1991-02-28 Fritz Egger Gmbh Elektroabscheider zum abscheiden von schwebstoffen aus gasen
DE3939714A1 (de) * 1989-12-01 1991-06-06 Baedje K H Meteor Gummiwerke Schlauch
WO1991011012A1 (en) * 1990-01-05 1991-07-25 Orscheln Co. Flexible synthetic plastic conduit
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE4206096A1 (de) * 1992-02-27 1993-09-02 Wolf Woco & Co Franz J Koaxialrohr
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
EP1186606B2 (de) 1995-11-17 2011-09-07 Gesellschaft für Biotechnologische Forschung mbH (GBF) Epothilon-Derivate, ihre Herstellung und Verwendung
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
WO1998008849A1 (de) 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
JP4274583B2 (ja) 1996-11-18 2009-06-10 ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング(ゲー・ベー・エフ) エポチロンc,d,e及びf、製造と薬剤
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1386922B1 (en) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
BR9807742B1 (pt) 1997-02-25 2010-12-14 n-àxidos de epotilâneos a e b, e processo para sua preparaÇço.
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
CA2286610C (en) 1997-04-18 2007-03-13 Studiengesellschaft Kohle Mbh Selective olefin metathesis of bifunctional or polyfunctional substrates in compressed carbon dioxide as reaction medium
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
AU8542898A (en) 1997-07-16 1999-02-10 Schering Aktiengesellschaft Thiazole derivatives, method for their production and use
DE59814067D1 (de) 1997-08-09 2007-09-06 Bayer Schering Pharma Ag Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
DE19747580A1 (de) 1997-10-28 1999-04-29 Siemens Ag Rangierfeld mit Anschlußleiste
US6365749B1 (en) * 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
SK287775B6 (sk) 1998-02-05 2011-09-05 Novartis Ag Farmaceutická formulácia obsahujúca epothilon, infúzny roztok a použitie farmaceutickej formulácie
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
DE19807505A1 (de) 1998-02-21 1999-08-26 Roland Man Druckmasch Bogenrotationsdruckmaschine mit Druckeinheiten für den Mehrfarbendruck und wenigstens einer Beschichtungseinheit
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
JP2002504540A (ja) 1998-02-25 2002-02-12 スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ エポチロンの合成、その中間体およびそのアナログ
WO2000000485A1 (de) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
AU5325699A (en) * 1998-08-12 2000-03-06 Proteus Inc. Ribbed core dual wall structure
BR9916833A (pt) 1998-12-22 2001-09-25 Novartis Ag Derivados de epotilona e seu uso como agentes antitumor
PE20010116A1 (es) 1999-04-30 2001-02-15 Schering Ag Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
US6605559B1 (en) 1999-09-29 2003-08-12 Daihatsu Motor Co., Ltd. Dimethyl ether reforming catalyst
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
MXPA03006485A (es) 2001-01-25 2003-09-22 Bristol Myers Squibb Co Formulacion parenteral que contiene analogos de epotilona.
EE05301B1 (et) 2001-01-25 2010-06-15 Bristol-Myers Squibb Company Meetod epotilooni analooge sisaldavate ravimvormide valmistamiseks ning nende kasutamine ravimi valmistamiseks
US9317043B2 (en) 2013-12-19 2016-04-19 Google Inc. Path based power generation control for an aerial vehicle

Also Published As

Publication number Publication date
US20040157897A1 (en) 2004-08-12
PL365610A1 (en) 2005-01-10
US6689802B2 (en) 2004-02-10
CA2418109A1 (en) 2002-02-21
AR034259A1 (es) 2004-02-18
ATE366735T1 (de) 2007-08-15
US20060063815A1 (en) 2006-03-23
AU2001281082B2 (en) 2007-01-04
GEP20053495B (en) 2005-04-25
TWI320040B (en) 2010-02-01
PL205628B1 (pl) 2010-05-31
US7153879B2 (en) 2006-12-26
NZ523722A (en) 2005-04-29
CN1269821C (zh) 2006-08-16
HK1052010A1 (en) 2003-08-29
US6982276B2 (en) 2006-01-03
EP1309597A2 (en) 2003-05-14
DE60129334D1 (en) 2007-08-23
JP5046467B2 (ja) 2012-10-10
USRE39251E1 (en) 2006-08-29
MY134129A (en) 2007-11-30
JP2004506638A (ja) 2004-03-04
LV13032B (en) 2003-12-20
BG66132B1 (bg) 2011-06-30
PE20020290A1 (es) 2002-04-03
HUP0300826A2 (hu) 2003-09-29
HRP20030190A2 (en) 2003-04-30
WO2002014323A2 (en) 2002-02-21
DK1309597T3 (da) 2007-10-22
SI21100A (sl) 2003-06-30
CA2418109C (en) 2011-09-27
IS6714A (is) 2003-02-11
IL153993A (en) 2009-07-20
WO2002014323A3 (en) 2002-05-02
AU8108201A (en) 2002-02-25
LT5138B (lt) 2004-06-25
IL153993A0 (en) 2003-07-31
ES2288518T3 (es) 2008-01-16
EE200300063A (et) 2004-12-15
LT2003017A (en) 2004-03-25
KR20030022411A (ko) 2003-03-15
CN1468243A (zh) 2004-01-14
CZ2003418A3 (cs) 2004-01-14
PT1309597E (pt) 2007-08-22
BR0113234A (pt) 2004-02-25
RU2272039C2 (ru) 2006-03-20
HRP20030190B1 (en) 2011-07-31
RO123296B1 (ro) 2011-06-30
SK1342003A3 (en) 2003-09-11
YU12103A (sh) 2006-08-17
KR100810342B1 (ko) 2008-03-07
CZ305523B6 (cs) 2015-11-18
IS2845B (is) 2013-08-15
ZA200300522B (en) 2004-04-20
DE60129334T2 (de) 2008-04-03
CY1107758T1 (el) 2013-06-19
UA75365C2 (en) 2006-04-17
SK287876B6 (sk) 2012-02-03
HUP0300826A3 (en) 2005-05-30
MXPA03001431A (es) 2004-05-04
EP1309597B1 (en) 2007-07-11
EE05273B1 (et) 2010-02-15
HU229314B1 (en) 2013-10-28
UY26886A1 (es) 2002-03-22
NO20030707L (no) 2003-04-15
SI21100B (sl) 2009-12-31
US20020188014A1 (en) 2002-12-12
BG107467A (bg) 2003-09-30
NO20030707D0 (no) 2003-02-14

Similar Documents

Publication Publication Date Title
NO328500B1 (no) Polymorfer av en epothilon-analog
AU2001281082A1 (en) Polymorphs of an epothilone analog
CA2737055C (en) Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hcv inhibitor
EP3557998B1 (en) Compouns, compositions and methods of use
DE69832294T2 (de) Epothilonderivate
DE60132309T2 (de) Amin-derivate zur behandlung von apoptosis
AU2020215380A2 (en) Heterocyclic compound and use thereof
CN104114542B (zh) 三唑并嘧啶化合物的合成
CN115443129A (zh) Kcnt1抑制剂和使用方法
JP2020536898A (ja) スピロ誘導体を調製するためのプロセス

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees